Marinus Announces Leadership Transition
February 26, 2019 09:00 ET
|
Marinus Pharmaceuticals, Inc.
RADNOR, Penn., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) (“Marinus” or the “Company”), a biopharmaceutical company dedicated to the development of innovative...
Marinus Pharmaceuticals to Present at the Leerink Healthcare Conference
February 20, 2019 07:30 ET
|
Marinus Pharmaceuticals, Inc.
RADNOR, Pa., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the “Company”), a biopharmaceutical company dedicated to the development of innovative therapeutics to...
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 05, 2019 16:00 ET
|
Marinus Pharmaceuticals, Inc.
RADNOR, Pa., Feb. 05, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative...
Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
January 25, 2019 16:00 ET
|
Marinus Pharmaceuticals, Inc.
RADNOR, Pa., Jan. 25, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative...
Marinus Pharmaceuticals Announces Pricing of Public Offering of Common Stock
December 12, 2018 20:26 ET
|
Marinus Pharmaceuticals, Inc.
RADNOR, Pa., Dec. 12, 2018 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) (“Marinus” or the “Company”) announced the pricing of an underwritten public offering of 12,000,000 shares...
Marinus Pharmaceuticals Announces Public Offering of Common Stock
December 11, 2018 16:01 ET
|
Marinus Pharmaceuticals, Inc.
RADNOR, Pa., Dec. 11, 2018 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS), (“Marinus” or the “Company”) today announced that it intends to offer and sell 12,000,000 shares of its...
Marinus Pharmaceuticals Announces Positive Ganaxolone Data in Women With Postpartum Depression
December 10, 2018 07:30 ET
|
Marinus Pharmaceuticals, Inc.
Ganaxolone was safe and well-tolerated Ganaxolone IV demonstrated fast-acting, robust and durable efficacy Interim data with ganaxolone oral supports IV to oral administration Conference call to be...
Marinus Pharmaceuticals Phase 2 Clinical Trial Data Show Long-term Effectiveness of Ganaxolone in Reducing Seizure Frequency in CDKL5 Deficiency Disorder Patients
December 04, 2018 07:30 ET
|
Marinus Pharmaceuticals, Inc.
Predictive biomarker also identified in PCDH19-related pediatric epilepsy RADNOR, Pa., Dec. 04, 2018 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the “Company”, “Marinus”), a...
Marinus Pharmaceuticals to Present Ganaxolone Clinical Trial Data in CDKL5 Deficiency Disorder and PCDH19-Related Epilepsy at AES
November 19, 2018 07:30 ET
|
Marinus Pharmaceuticals, Inc.
RADNOR, Pa., Nov. 19, 2018 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative...
Marinus Pharmaceuticals Provides Business Update and Third Quarter 2018 Financial Results
October 29, 2018 07:30 ET
|
Marinus Pharmaceuticals, Inc.
RADNOR, Pa., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (“Marinus” or “Company”), a biopharmaceutical company dedicated to the development of innovative...